The Architecture of Rest: What Sleep Research Actually Shows

A sedative's job is to lower arousal so that sleep can begin. The compounds in this reference are studied for something narrower: the timing of the night, the stress tone going into it, and the hormones released inside it.

That is also why the claims around them need care. Much of what circulates about sleep peptides is extrapolated from animal work, from a change in a hormone level, or from small human studies that are decades old. Below, compound by compound, is what the research actually measured, in what model, and how far it goes.

In 1968, researchers sampling blood through the night found a growth hormone peak lasting one and a half to three and a half hours that arrived with the onset of deep sleep in seven of eight young adults, and moved later when sleep was delayed (Takahashi et al., 1968). In men, roughly 70% of the day's growth hormone output happens in early sleep. In women the link is looser and more variable.

In 149 healthy men, slow-wave sleep fell from 18.9% of the night at ages 16 to 25 to 3.4% at ages 36 to 50, with growth hormone secretion falling alongside it (Van Cauter et al., 2000). That link is why growth hormone compounds come up in sleep research at all. Here is what has actually been tested:

In 1977, Schoenenberger and Monnier in Basel recovered a nine-amino-acid peptide from the blood of rabbits whose thalamus was being electrically stimulated to induce sleep. Infused into the brains of other rabbits, it raised delta-wave EEG activity by about a third. They named it for that effect.

What followed is more interesting than the name. A 1980 rat study found no increase in sleep or delta activity at all (Tobler & Borbely, 1980). Much of the "DSIP-like" signal once measured in tissue was later traced to an unrelated protein, and a 2006 review in the Journal of Neurochemistry called DSIP a still unresolved riddle.

The human work is a handful of small studies, mostly from the 1980s, of six to eighteen people each, most of them from the original Basel group. Independent double-blind trials reported effects that were weak or of little clinical significance, and in the one study that broke sleep down by stage, the extra sleep was light stage 2 sleep; slow-wave and REM sleep did not change (Monti et al., 1987). The chemistry is solid. The question is still open, which is exactly what makes it a research compound.

Epitalon is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, designed in St. Petersburg from the makeup of a pineal gland extract. In aged rhesus monkeys, the group that developed it reported higher night-time melatonin after a short course, with no change in young animals. Almost all Epitalon research comes from that one network. It has no sleep, jet-lag or shift-work study in any species, and no registered clinical trial. Even its cell studies disagree: one group reported more melatonin from cultured rat pineal cells, while a Paris laboratory found no change in melatonin released from isolated rat pineal glands.

Selank is a seven-amino-acid peptide built from tuftsin, a fragment of an antibody protein, with a short tail added for stability. It was developed in Moscow and studied there as an anxiolytic, mostly in small Russian-language trials against benzodiazepines, which is why it appears in conversations about the stress side of sleep. No published study has measured sleep as an outcome.

Across 20 studies, people with chronic insomnia had moderately higher cortisol than good sleepers (Dressle et al.). That is an association, not proof of cause, but it is why three compounds outside the peptide catalog keep coming up in the same conversation.

DSIP, Selank, Epitalon and CJC-1295 + Ipamorelin are experimental research compounds. None is FDA-approved, and their safety in humans has not been established through large-scale clinical trials.

All Revitalized research compounds are sold strictly for research use. Not for human consumption, diagnostic, or therapeutic use. Standard institutional biosafety guidelines apply.

Takahashi Y, Kipnis DM, Daughaday WH (1968). Journal of Clinical Investigation, 47(9), 2079–2090. PMID 5675428.

Van Cauter E, Leproult R, Plat L (2000). JAMA, 284(7), 861–868. PMID 10938176.

Steiger A, et al. (1992). Neuroendocrinology, 56(4), 566–573. PMID 1361964.

Copinschi G, et al. (1997). Neuroendocrinology, 66(4), 278–286. PMID 9349662.

Ionescu M, Frohman LA (2006). Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. PMID 17018654.

Schoenenberger GA, Monnier M (1977). Proceedings of the National Academy of Sciences, 74(3), 1282–1286. PMID 265572.

Tobler I, Borbely AA (1980). Waking and Sleeping, 4(2), 139–153. PMID 7405185.

Kovalzon VM, Strekalova TV (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97(2), 303–309. PMID 16539679.

Monti JM, et al. (1987). International Journal of Clinical Pharmacology Research, 7(2), 105–110. PMID 3583493.

Goncharova ND, Vengerin AA, Shmaliĭ AV, Khavinson VKh (2003). Advances in Gerontology, 12, 121–127 (in Russian). PMID 14743609.

Filatova E, et al. (2017). Frontiers in Pharmacology, 8, 89. PMID 28293190.

Feng Y, et al. (2010). British Journal of Pharmacology, 161(1), 113–126. PMID 20718744.

Slutsky I, et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. PMID 20152124.